Next, we analyzed the effect of high-risk genetic mutations for the progression of myelodysplastic syndrome to AML [26], that is, wild type SF3B1 or mutations in SRSF2, RUNX1, U2AF1, ASXL1, and TP53, on the survival outcomes in the MF cohort (Figure 4). This evidence concerns the gene SRSF2 and myelodysplastic syndrome.